Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability. Its lead product candidates include XMT-1522, an ADC targeting HER2-expressing tumors, which is in Phase I clinical trial for treating patients with breast cancer, non-small-cell-lung-cancer (NSCLC), and gastric cancer; and XMT-1536, an ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, NSCLC, and other cancers. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck KGaA; and Asana BioSciences, LLC. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2002 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-498-0020
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$17.55 million
Profitability
Miscellaneous
Employees78
OptionableNot Optionable
Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions
What is Mersana Therapeutics' stock symbol?
Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."
How were Mersana Therapeutics' earnings last quarter?
Mersana Therapeutics Inc (NASDAQ:MRSN) released its earnings results on Wednesday, August, 15th. The company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.58) by $0.04. The company had revenue of $4.19 million for the quarter, compared to the consensus estimate of $3.74 million. Mersana Therapeutics had a negative return on equity of 110.44% and a negative net margin of 440.47%. View Mersana Therapeutics' Earnings History.
When is Mersana Therapeutics' next earnings date?
What price target have analysts set for MRSN?
6 Wall Street analysts have issued 1 year price objectives for Mersana Therapeutics' shares. Their predictions range from $14.00 to $61.00. On average, they expect Mersana Therapeutics' share price to reach $26.80 in the next year. This suggests a possible upside of 298.2% from the stock's current price. View Analyst Price Targets for Mersana Therapeutics.
What is the consensus analysts' recommendation for Mersana Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mersana Therapeutics.
Has Mersana Therapeutics been receiving favorable news coverage?
News coverage about MRSN stock has been trending neutral on Saturday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mersana Therapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.
Are investors shorting Mersana Therapeutics?
Mersana Therapeutics saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 589,489 shares, a decrease of 48.1% from the January 15th total of 1,136,169 shares. Based on an average daily volume of 138,454 shares, the short-interest ratio is currently 4.3 days. Approximately 5.6% of the shares of the company are short sold. View Mersana Therapeutics' Current Options Chain.
Who are some of Mersana Therapeutics' key competitors?
Some companies that are related to Mersana Therapeutics include Vectura Group (VEGPF), Eagle Pharmaceuticals (EGRX), Basilea Pharmaceutica (BPMUF), CymaBay Therapeutics (CBAY), Crinetics Pharmaceuticals (CRNX), Assembly Biosciences (ASMB), AMAG Pharmaceuticals (AMAG), Lexicon Pharmaceuticals (LXRX), Kura Oncology (KURA), Karyopharm Therapeutics (KPTI), Aurinia Pharmaceuticals (AUPH), Akorn (AKRX), Urogen Pharma (URGN), Flexion Therapeutics (FLXN) and ChemoCentryx (CCXI).
Who are Mersana Therapeutics' key executives?
Mersana Therapeutics' management team includes the folowing people:
- Ms. Anna Protopapas, Pres, CEO & Director (Age 55)
- Mr. Timothy B. Lowinger, Sr. VP & Chief Scientific Officer (Age 55)
- Mr. Mikhail Papisov Ph.D., Co-Founder
- Mr. Wayne Foster, VP of Fin.
- Mr. David A. Spellman, Chief Financial Officer (Age 42)
When did Mersana Therapeutics IPO?
(MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Mersana Therapeutics' major shareholders?
Mersana Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.37%), Northern Trust Corp (0.60%), Geode Capital Management LLC (0.55%), Hikari Power Ltd (0.37%), Two Sigma Investments LP (0.29%) and Millennium Management LLC (0.19%). Company insiders that own Mersana Therapeutics stock include M James Barrett and Timothy B Lowinger. View Institutional Ownership Trends for Mersana Therapeutics.
Which major investors are selling Mersana Therapeutics stock?
Which major investors are buying Mersana Therapeutics stock?
MRSN stock was purchased by a variety of institutional investors in the last quarter, including Hikari Power Ltd, Two Sigma Investments LP, Bank of America Corp DE, Bank of New York Mellon Corp, Geode Capital Management LLC and Rhumbline Advisers. View Insider Buying and Selling for Mersana Therapeutics.
How do I buy shares of Mersana Therapeutics?
Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mersana Therapeutics' stock price today?
One share of MRSN stock can currently be purchased for approximately $6.73.
How big of a company is Mersana Therapeutics?
Mersana Therapeutics has a market capitalization of $156.01 million and generates $17.55 million in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Mersana Therapeutics employs 78 workers across the globe.
What is Mersana Therapeutics' official website?
How can I contact Mersana Therapeutics?
Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]
MarketBeat Community Rating for Mersana Therapeutics (NASDAQ MRSN)
MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote "Outperform" if you believe MRSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
